Jefferies Maintains Buy on GSK, Raises Price Target to $53
Portfolio Pulse from Benzinga Newsdesk
Jefferies analyst Peter Welford maintains a Buy rating on GSK (NYSE:GSK) and raises the price target from $52.5 to $53.
July 02, 2024 | 5:58 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Jefferies analyst Peter Welford maintains a Buy rating on GSK and raises the price target from $52.5 to $53.
The raised price target and maintained Buy rating from a reputable analyst at Jefferies is likely to boost investor confidence in GSK, potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100